Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Conditions: Functioning Lung Carcinoid Tumor; Locally Advanced Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Typical Carcinoid Tumor; Metastatic Lung Neuroendocrine Neoplasm; Non-Functioning Lung Carcinoid Tumor; Rec urrent Lung Neuroendocrine Neoplasm; Unresectable Lung Neuroendocrine Neoplasm Interventions: Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials